ALCAM and prostate cancer: Moreover, ALCAM mediates the resistance of prostate cancer to enzalutamide (ENZA), a second-generation androgen receptor inhibitor frequently used for treating metastatic castration-resistant prostate cancer and ALCAM gene silencing in drug-resistant cells could enhance ENZA sensitivity (Csizmarik et al., 2022).